HilleVax Revenue and Competitors

Location

#5481

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • HilleVax's estimated annual revenue is currently $17.2M per year.(i)
  • HilleVax's estimated revenue per employee is $155,000

Employee Data

  • HilleVax has 111 Employees.(i)
  • HilleVax grew their employee count by 44% last year.

HilleVax's People

NameTitleEmail/Phone
1
COO & Co-FounderReveal Email/Phone
2
CEO, President and ChairReveal Email/Phone
3
VP QualityReveal Email/Phone
4
VP Clinical DevelopmentReveal Email/Phone
5
SVPReveal Email/Phone
6
VP, Program ManagementReveal Email/Phone
7
Chief Medical OfficerReveal Email/Phone
8
Director, Analytical DevelopmentReveal Email/Phone
9
Director, FP&AReveal Email/Phone
10
Director, Research & DiscoveryReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is HilleVax?

keywords:N/A

N/A

Total Funding

111

Number of Employees

$17.2M

Revenue (est)

44%

Employee Growth %

N/A

Valuation

N/A

Accelerator

HilleVax News

2022-04-17 - Norovirus vaccine developer HilleVax files for $100M IPO

HilleVax has been developing vaccine called HIL-214 for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection...

2022-04-13 - HilleVax Targets $100 Million IPO For Acute Gastroenteritis Vaccine

HilleVax has booked fair market value investment of $158 million in convertible promissory notes from investors including Frazier Life Sciences...

2022-04-06 - HilleVax, a Biopharma Developing Vaccines, Is Going Public

HilleVax, which was formed by Takeda Pharmaceutical and private-equity firm Frazier Healthcare Partners, is going public.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.1M111-31%N/A
#2
$15M111-6%N/A
#3
$19.1M11114%N/A
#4
$30M1114%N/A
#5
$20M11131%N/A